Canada - français - Health Canada

bristol-myers squibb canada - fédratinib (chlorhydrate de fédratinib) - capsule - 100mg - fédratinib (chlorhydrate de fédratinib) 100mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agents antinéoplasiques - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - fedratinibum - gélules - fedratinibum 100 mg ut fedratinibi dihydrochloridum monohydricum, cellulosum microcristallinum silicificatum, natrii stearylis fumaras corresp. natrium 0.18 mg, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - primäre oder sekundäre myelofibrose - synthetika